WO2011085811A1 - Procédé d'évaluation de la réponse de patients souffrant de polyarthrite rhumatoïde à une thérapie et procédé de diagnostic de la gravité de la maladie - Google Patents

Procédé d'évaluation de la réponse de patients souffrant de polyarthrite rhumatoïde à une thérapie et procédé de diagnostic de la gravité de la maladie Download PDF

Info

Publication number
WO2011085811A1
WO2011085811A1 PCT/EP2010/050402 EP2010050402W WO2011085811A1 WO 2011085811 A1 WO2011085811 A1 WO 2011085811A1 EP 2010050402 W EP2010050402 W EP 2010050402W WO 2011085811 A1 WO2011085811 A1 WO 2011085811A1
Authority
WO
WIPO (PCT)
Prior art keywords
soluble
sample
response
patients
protein
Prior art date
Application number
PCT/EP2010/050402
Other languages
English (en)
Inventor
Bernard Lauwerys
Valérie BADOT
Frédéric HOUSSIAU
Benoît VAN DEN EYNDE
Original Assignee
Universite Catholique De Louvain
Cliniques Universitaires Saint Luc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique De Louvain, Cliniques Universitaires Saint Luc filed Critical Universite Catholique De Louvain
Priority to PCT/EP2010/050402 priority Critical patent/WO2011085811A1/fr
Publication of WO2011085811A1 publication Critical patent/WO2011085811A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention is directed to methods for determining the response to a treatment of individuals suffering from rheumatoid arthritis (RA).
  • the invention relates to methods to predict the responsiveness of a patient with rheumatoid arthritis to methotrexate, and biologies including, but not limited to, a TNF blocking drug, IL-1 blocking agents and/or IL-17 blocking agents.
  • Rheumatoid arthritis has a worldwide distribution and involves all ethnic groups. Although the disease can occur at any age, the prevalence increases with age and the peak incidence is between the fourth and sixth decade. The prevalence estimates for the North American population vary from 0.3% to 1.5%. Today, over 2,500,000 individuals are diagnosed with rheumatoid arthritis in the United States alone, with some statistics indicating from 6.5 to 8 million potentially afflicted with the disease. Women are affected 2-3 times more often than men.
  • rheumatoid arthritis The early symptoms of rheumatoid arthritis are mostly joint specific such as painful joints with joint swelling or tenderness, but may also include rather non-specific manifestations like stiffness, fever, subcutaneous nodules, and fatigue. Very characteristic is the symmetric involvement of joints. The joints of the hands, feet, knees and wrists are most commonly affected, with eventual involvement of the hips, elbows and shoulders. As the disease progresses, any type of motion becomes very painful and difficult leading eventually to a loss of function of the involved joints. The more severe cases of rheumatoid arthritis can lead to intense pain and joint destruction. Some 300,000 bone and joint replacement surgical procedures are performed annually in an effort to alleviate the pain and mobility loss resultant from arthritis related joint destruction.
  • RA is a chronic inflammatory disease of the synovium that can lead to severe joint damage if insufficiently treated.
  • central to the pathogenesis of RA is the proliferation of synovial fibroblasts (synovial "pannus") in response to the production of autocrine, but also paracrine molecules produced by infiltrating mononuclear cells.
  • proinflammatory cytokines such as TNF-alpha, IL-1-beta, IL-6 or IL-17 play an important role, and this observation led to the development of targeted therapies.
  • TNF blocking agents are used routinely in RA patients who have failed first-line Disease Modifying Anti- Rheumatic Drugs (DMARD) therapy.
  • the present invention provides several methods to predict or estimate the likelihood or probability that a patient with rheumatoid arthritis will respond with positive or favorable clinical results to treatment with methotrexate or with biological agents including, but not limited to, TNF blocking agent, IL-1 blocking agents and/or IL-17 blocking agents and to diagnose the RA disease severity or progression in a subject.
  • the invention is based on the unexpected finding that in RA patients, especially in patients with severe or advanced RA, the FLS cells of the synovial tissue show an increased expression of a specific transcript of the IL7 receptor, lacking exon 6.
  • the protein derived from said transcript is a soluble truncated form of the IL7 receptor, which is secreted by the FLS cells and is capable of binding IL7, thereby functioning as an IL7 sequester molecule.
  • the inventors found that said soluble IL-7 receptor protein is induced in FLS by pro-inflammatory cytokines, such as TNF-alpha, IL-1 beta or IL-17 and synergistic combinations of these cytokines, which play an important pathogenic role in RA.
  • the inventors showed that surprisingly said secreted soluble IL7 receptor protein fragment can be detected in synovial fluid and, more surprisingly, in serum samples of both healthy subjects and RA patients, wherein the amount or concentration of the protein increases with the disease severity and with resistance to treatment with methotrexate (in early RA patients) or biologies including, but not limited to, TNF-blocking agents (especially in DMARD-resistant patients), IL- 1 blocking and/or IL-17 blocking agents (in DMARD-resistant patients).
  • TNF-blocking agents especially in DMARD-resistant patients
  • IL- 1 blocking and/or IL-17 blocking agents in DMARD-resistant patients.
  • One aspect of the invention thus provides a method for predicting the response to a treatment with methotrexate, a TNF blocking agent, IL-1 blocking agents and/or IL-17 blocking agents, in a patient comprising or consisting of evaluating the amount of soluble IL7R protein in a sample of the patient, preferably a bodily fluid sample of the patient, more preferably a synovial fluid sample or a blood, or serum sample.
  • the invention provides a method for evaluating the disease severity of a RA patient comprising or consisting of evaluating the amount of soluble IL7R protein in a sample of the patient, preferably a bodily fluid sample of the patient, more preferably a synovial fluid sample or a blood, or serum sample.
  • Another aspect of the invention relates to a method to determine the probability of a positive clinical response in a patient, with early rheumatoid arthritis, to treatment with a methotrexate based on the amount of soluble IL7 receptor protein in a serum or synovial sample of said patient.
  • Another aspect of the invention relates to a method to determine the probability of a positive clinical response in a DMARD-resistant patient, to treatment with IL-1 blocking agents and/or IL-17 blocking agents based on the amount of soluble IL7 receptor protein in a serum or synovial sample of said patient.
  • the present inventors have designed methods based on the identification of the level of the slL7R biomarker in serum as being predictive of the response to TNF blocking agents in severe RA, and that are useful for determining whether an individual with rheumatoid arthritis will be a poor, moderate or good responder to TNF blocking therapy.
  • the level of soluble IL7R protein secreted by fibroblast-like synovial cells (FLS) in synovial fluid has the potential to be useful for identifying the probability of a positive clinical response in a patient, with rheumatoid arthritis, to treatment with a TNF blocking drug.
  • the methods according to the present invention is based on the comparison of the level, amount or concentration of the slL7R protein as compared to standard values that can be determined beforehand or simultaneously based on samples from pre-diagnosed or predetermined samples using an identical assay.
  • the invention further provides for a method for predicting the response to a treatment with methotrexate in a subject with early RA comprising the steps of:
  • step (a) measuring in a sample from said patient the amount of soluble IL-7R, and (b) predicting the response to the treatment with methotrexate in said patient by evaluating the results of step (a).
  • the invention thus provides for a method for predicting the response to a treatment with a TNF blocking agent in a DMARD-resistant RA patient comprising the steps of:
  • step (b) predicting the response to the treatment with the TNF blocking agent in said patient by evaluating the results of step (a).
  • the invention further provides for a method for predicting the response to a treatment with IL-1 blocking agents and/or IL-17 blocking agents in a subject with DMARD-resistant RA comprising the steps of:
  • step (b) predicting the response to the treatment with IL-1 blocking agents and/or IL-17 blocking agents in said patient by evaluating the results of step (a).
  • the invention further provides for a method for diagnosing the RA disease severity in a subject comprising the steps of:
  • step (b) predicting the disease severity in said patient by evaluating the results of step (a).
  • measuring the amount of slL7R is preferably performed by measuring the concentration of soluble IL-7R protein in a blood, serum, or synovial fluid sample of said subject.
  • said method comprises the steps of:
  • iii) predicting the response to a treatment with methotrexate, a TNF blocking agent, IL-1 blocking agent and/or IL-17 blocking agent or the RA disease severity in a subject when detectable soluble IL-7R is present in the sample or when the amount of soluble IL-7R in the sample is greater than or equal to a threshold value.
  • the amount of the slL7R protein is detected using a reagent which specifically binds with said protein, preferably selected from the group consisting of: an aptamer, a photoaptamer, a protein, a peptide, a peptidomimetic, an antibody or a fragment or a derivative thereof, a polyclonal antibody, a monoclonal antibody, a humanised or a chimeric antibody, an engineered antibody, or a biologically functional antibody fragment sufficient for binding to the soluble form of the IL7R alpha chain protein, or wherein the amount of soluble IL7R is measured using any of biochemical assay, immunoassay, surface plasmon resonance, fluorescence resonance energy transfer, bioluminescence resonance energy transfer or quenching is detected.
  • a reagent which specifically binds with said protein preferably selected from the group consisting of: an aptamer, a photoaptamer, a protein, a peptide, a peptidomimetic, an
  • step of determining the threshold value of responders vs. non-responders in any one of the above methods can optionally be determined before step (i) by:
  • step of determining the threshold value of low vs. high RA disease severity is optionally determined before step (i) by:
  • said sample is a serum sample. In another embodiment, said sample is a synovial fluid sample.
  • kits for predicting the response of a RA patient to a treatment with methotrexate, a TNF blocking agent, IL-1 blocking agent and/or IL-17 blocking agent comprising:
  • the invention provides for the use of the kit as described herein, in a method for predicting the response of a subject to a treatment with methotrexate, a TNF blocking agent, IL-1 blocking agent and/or IL-17 blocking agents as described herein.
  • kits for predicting the severity of the RA condition of a RA patient comprising:
  • the invention provides for the use of the kit as described herein, in a method for predicting the severity of the RA condition of a subject as described herein.
  • the method of the invention comprises:
  • reference samples preferably reference samples, from reference subjects which are poor, moderate and good responder to TNF inhibition
  • said biological sample preferably said sample, is from a poor, moderate or good responder to TNF inhibition.
  • Figure 1 FLS and activated CD4 T cells produce two IL-7R alpha-chain isoforms.
  • IL-7R Western Blots on protein extracts from FLS and PBMC, and IL-7R PCR on cDNA from TNF-alpha and IL-1 -beta-activated FLS (1 ), IL-2 and PHA activated CD4 T cells (2), antigen-activated CD8 T cell clones (3) and B-EBV cells (4). Arrows indicate the expected sizes of the membrane-bound IL-7R.
  • Figure 2 Pro-inflammatory cytokines stimulate slL-7R production by FLS.
  • Figure 4 slL-7R serum concentrations predict response to TNF blockade in DMARD- resistant RA patients.
  • slL-7R titers measured by sandwich ELISA in duplicate baseline serum samples obtained in DMARD-resistant RA patients treated with 3 mg/kg infliximab. Patients were categorized in responders versus non-responders according to EULAR response criteria.
  • slL-7R titers measured by sandwich ELISA in duplicate baseline serum samples obtained in early RA patients treated with methotrexate. Patients were categorized in responders versus non-responders according to EULAR response criteria.
  • Figure 6 represents in (A) SEQ ID NO:1 (mRNA sequence corresponding to the membrane bound form of IL-7R ) in (B) SEQ ID NO:2 (amino acid sequence of the membrane bound form of lL-7R).
  • Figure 7 represents in (A) SEQ ID NO:3 (mRNA sequence corresponding to the soluble form of IL-7R), and in (B) SEQ ID NO:4 (amino acid sequence corresponding to the soluble form of IL-7R).
  • the present inventors show that serum and synovial fluid levels of a soluble form of the interleukin-7 receptor alpha-chain (slL-7R) are significantly associated with response to therapy in early RA patients treated with methotrexate and in DMARD-resistant RA patients treated with TNF blocking agents.
  • Soluble IL-7R is produced by RA synovial fibroblasts after exposure to pro-inflammatory cytokines and, to a lesser extent, by activated CD4 T cells.
  • slL-7R By reflecting synovial cell exposure to TNF-alpha, IL-1 -beta, IL-17 and synergistic combinations of these cytokines, slL-7R is identified as a marker of disease severity and response to therapy in RA, detectable in the serum and synovial fluid of the subject.
  • the inventors first studied the expression of the IL-7R alpha-chain in synovial cells from RA patients, and found that cultured fibroblast-like synovial cells (FLS) produce the secreted form of the molecule. Although PCR and Western Blot experiments indicate that FLS also display a positive signal for the full length IL-7R alpha-chain, it could not be detected by flow cytometry at the cell surface of resting or stimulated cells, and neither was any proliferative effect or induction of cytokines by FLS found in response to IL-7 (data not shown).
  • FLS fibroblast-like synovial cells
  • the soluble IL-7R has been described in fibroblast cell lines as the result of alternative splicing of the gene, leading to a deletion of exon 6 that contains the transmembrane domain (Goodwin et al., Cell 1990; 60: 941-51 ; Pleiman et al., Mol Cell Biol 1991 ; 1 1 : 3052-9).
  • the present invention shows that addition of pro-inflammatory cytokines, such as TNF-alpha and IL-1-beta, or various combinations of TNF-alpha, IL-1-beta and IL-17, stimulate the expression and secretion of slL-7R by fibroblast-like synovial cells (FLS).
  • FLS fibroblast-like synovial cells
  • soluble IL-7R is able to bind and inhibit IL-7.
  • the present invention confirms that such a mechanism is also present in the context of RA and demonstrated that, while IL-7 stimulates synovial CD4 T-cell proliferation in response to FLS, IL-7 inhibition by a slL-7R-Fc fusion protein induces the opposite effect. Taken together, these results indicate that slL-7R is induced by pro-inflammatory cytokines in FLS and plays a role in a negative feed-back loop through the inhibition of T-cell proliferation and activation.
  • soluble IL-7R is produced by alternative splicing of the IL-7 gene in T-cells, and not by proteolytic cleavage from the surface of T-cells.
  • the present invention established that synovial fluid and serum levels of the soluble IL7R molecule are higher in patients with early RA as compared to healthy subjects and are even higher in DMARD-resistant RA patients, an observation consistent with the data indicating that soluble IL-7R reflects synovial fibroblast activation and, to a lesser extent, CD4 T-cell activation.
  • serum soluble IL-7R is a promising clinical biomarker that can aid the individual therapeutic decision-making process in RA in order to evaluate the usefulness of therapy with not only TNF-blocking agents, but also methotrexate and potentially also other biologicals such as IL-1 and IL-17 blocking agents.
  • the slL7R is a marker of severity in RA because it reflects synovial cell exposure to cytokines with a strong pro-inflammatory action, such as TNF, IL-1 , IL-17 and potentially other cytokines.
  • the slL7R level therefore also predicts absence of response to therapy in that the higher the amount of these cytokines in the synovium, the harder it will be for (any) therapy to counteract them. It is therefore expected that high baseline slL7R serum levels could actually very well predict absence of response to IL-1 blockade or IL-17 blockade and other biologies such as rituximab (Mabthera)therapy which down-regulates IL-17 production in the synovium (data not shown), CTLA4-lg (Orencia), or tocilizumab (Ro-Actemra).
  • soluble IL7R as a biomarker in clinical practice would have an important impact in terms of patients' outcomes and drug expenses. In the absence of selection, 25% of the patients described in this work did not respond to TNF blockade, a proportion in accordance with published data. If the patients had been selected based on baseline soluble IL-7R serum levels, the proportion of non-responders would have dropped to 1 1 %, while only 5% would have been switched to an alternative therapy although they would have responded to TNF blockade. Such differences are highly significant from a clinical point of view and make the serum soluble IL-7R an important new clinical biomarker in RA.
  • biomolecule that permits the expression level of a gene or an amount of protein to be determined.
  • biomolecules include, but are not limited to total RNA, mRNA, and polypeptides, and derivatives of these molecules such as cDNAs and ESTs.
  • a biological sample can comprise a cell or a group of cells.
  • Samples may include, without limitation, whole blood, plasma, serum, red blood cells, white blood cells (e.g., peripheral blood mononuclear cells), saliva, urine, stool (i.e., faeces), tears, sweat, sebum, nipple aspirate, ductal lavage, tumour exudates, joint or synovial fluid, cerebrospinal fluid, lymph, fine needle aspirate, amniotic fluid, any other bodily fluid, cell lysates, cellular secretion products, inflammation fluid, semen and vaginal secretions.
  • Preferred samples may include ones comprising soluble IL7R protein or mRNA coding therefore in detectable quantities.
  • the sample for protein detection is whole blood or preferably plasma (i.e.
  • a preferred sample for mRNA detection is a sample comprising cells expressing the mRNA encoding for the soluble form of the IL7R, i.e. the splice variant as defined herein.
  • said sample is joint fluid, synovial fluid, more preferably a sample of FLS-cells (fibroblast-like synovial cells).
  • the sample can, of course, be subjected to a variety of well-known post-collection preparative and storage techniques (e. g. fixation, storage, freezing, lysis, homogenization, DNA or RNA extraction, ultrafiltration, concentration, evaporation, centrifugation, etc.) prior to determining the level of expression in the sample.
  • the RNA may be stabilized using known RNA stabilizers upon or shortly after obtaining the sample.
  • the methods of the present invention are particularly useful for subjects with rheumatic arthritis, preferably severe rheumatic arthritis (e.g. for anti-TNF-blocking therapy evaluation) or early RA (e.g. for methotrexate therapy evaluation) , defined by appropriate RA severity scales known in the art and defined herein.
  • the terms “subject”, “patient” or “individual” refer to any vertebrate species.
  • the term subject encompasses warm-blooded vertebrates, more preferably mammals. More particularly contemplated are mammals such as humans, as well as animals such as carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), poultry, ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses.
  • a method means one method or more than one method.
  • level or “expression level” refers to the expression level data that can be used to compare the expression levels of different genes among various samples and/or subjects.
  • amount or “concentration” of certain protein refers respectively to the effective (i.e. total protein amount measured) or relative amount (i.e. total protein amount measured in relation to the sample size used) of the protein in a certain sample.
  • slL7R protein or "soluble IL7R protein” refers to the soluble form of the IL7 receptor alpha chain protein, which is the result of an mRNA isoform or splice variant of the gene encoding for the IL7 receptor alpha chain protein, as described by Goodwin et al., 1990 and Pleiman et al., 1991 (Goodwin et al., Cell 1990; 60: 941-51 ; Pleiman et al., Mol Cell Biol 1991 ; 1 1 : 3052-9).
  • the soluble form is the product of a splice variant originating from deletion of exon 6, encoding the transmembrane region.
  • gene encoding for the slL7R protein or "isoform encoding the soluble IL7R protein” refers to the mRNA isoform or splice variant of the gene encoding for the IL7 receptor alpha chain protein, as described by Goodwin et al., 1990 and Pleiman et al., 1991 (Goodwin et al., Cell 1990; 60: 941-51 ; Pleiman et al., Mol Cell Biol 1991 ; 1 1 : 3052-9). In essence, said splice variant originates from deletion of exon 6, encoding the transmembrane region.
  • the mRNA sequence corresponding to the membrane bound form is represented by SEQ ID NO:1
  • the resulting amino acid sequence is represented by SEQ ID NO:2.
  • the mRNA sequence corresponding to the soluble form is represented by SEQ ID NO:3
  • the resulting amino acid sequence is represented by SEQ ID NO:4.
  • the present invention includes methods and kits for detecting the presence and/or amount of a certain splice variant of the gene encoding the IL7R alpha chain protein, especially the isoform missing exon 6 encoding the soluble IL7R protein fragment.
  • fragment shall be understood to mean a nucleic acid that is the same as part of, but not all of a nucleic acid that forms a gene.
  • fragment also encompasses a part, but not all of an intergenic region.
  • increased expression and “decreased expression” refers to expression of the gene in a sample, at a greater or lesser level, respectively, than the level of expression of said gene (e. g. at least two-fold greater or lesser level) in a control (reference sample).
  • the gene is said to be up-regulated or over-expressed or down-regulated or under-expressed if either the gene is present at a greater or lesser level, respectively, than the level in a control.
  • Expression of a gene in a sample is "significantly" higher or lower than the level of expression of a gene in a control if the level of expression of the gene is greater or less, respectively, than the level by an amount greater than the standard error of the assay employed to assess expression, and preferably at least twice, and more preferably three, four, five or ten times that amount.
  • expression of the gene in the sample can be considered “significantly” higher or lower than the level of expression in a control if the level of expression is at least about two, and preferably at least about three, four, or five times, higher or lower, respectively, than the level of expression of the gene in said control.
  • the terms “increased amount or concentration” or “decreased amount or concentration” of a certain protein respectively refer to a higher or lower presence of the amount of protein in a certain sample as compared to the level in a control sample.
  • the amount or concentration of the protein is "significantly" higher or lower than the amount or concentration of a protein in a control sample if said change exceeds the standard error of the assay employed to assess the amount or concentration of the protein, and is preferably at least 1.5, 2, 3, 4, 5, or 10 times the control amount or concentration.
  • profile refers to a repository of the expression level data that can be used to compare the expression levels of different genes among various subjects.
  • predicting or “prediction”
  • diagnosis or “diagnosis”
  • prognosticating or “prognosis”
  • predicting generally refer to an advance declaration, indication or foretelling of a disease or condition in a subject not (yet) having said disease or condition.
  • a prediction of a disease or condition in a subject may indicate a probability, chance or risk that the subject will develop said disease or condition, for example within a certain time period or by a certain age.
  • Said probability, chance or risk may be indicated inter alia as an absolute value, range or statistics, or may be indicated relative to a suitable control subject or subject population (such as, e.g., relative to a general, normal or healthy subject or subject population).
  • the probability, chance or risk that a subject will develop a disease or condition may be advantageously indicated as increased or decreased, or as fold-increased or fold-decreased relative to a suitable control subject or subject population.
  • the term "prediction of response" in a subject may also particularly mean that the subject has a 'positive' prediction of responding to treatment with methotrexate, TNF- blocking agents, IL-1 blocking agents and/or IL-17 blocking agents.
  • prediction of no response in a subject may particularly mean that the subject has a 'negative' prediction of responding to treatment with methotrexate, TNF-blocking agents, IL-1 blocking agents and/or IL-17 blocking agents vis-a-vis a control subject or subject population.
  • RARBIS rheumatoid arthritis medical records based index of severity
  • DAS28 van der Heijde et al., 1993, J Rheumatol 20:579-581 and Prevoo et al., 1995, Arthritis Rheum, 38:44-48
  • RASS Bardwell et al., 2002, Rheumatology (Oxford), Jan;41 (1 ):38-45
  • any one of these scales can be used to distinguish between healthy subjects, early RA subjects, DMARD-resistant progressive RA patients. All scales are generally designed around three visual analogue scales: Disease Activity, Functional Impairment and Physical Damage, based e.g. on number of swollen joints, number of tender joints, erythrocyte sedimentation rate (ESR), and general health. Preferably, the severity is established based on persistant disease activity (i.e. elevated DAS28-CRP scores) despite therapy, leading to an increased probability of radiological damage, joint destruction and, finally, disability.
  • DAS28-CRP scores persistant disease activity
  • the level of expression of said gene or fragment thereof in (vivo or in) said sample is assessed by detecting the level of expression of the soluble form of the IL-7 alpha chain protein or a fragment thereof.
  • the level of expression of said protein or fragment thereof is detected using a binding agent which specifically binds with said protein or fragment thereof.
  • binding agent is defined as specifically binding to the soluble IL7 receptor protein alpha chain or a fragment thereof and may include inter alia an antibody, aptamer, photoaptamer, protein, peptide, peptidomimetic or a small molecule
  • specifically bind means that an agent (denoted herein also as “specific-binding agent”) binds to one or more desired molecules or analytes, such as to one or more proteins, polypeptides or peptides of interest or fragments thereof substantially to the exclusion of other molecules which are random or unrelated, and optionally substantially to the exclusion of other molecules that are structurally related.
  • an agent denoted herein also as “specific-binding agent”
  • bind binds to one or more desired molecules or analytes, such as to one or more proteins, polypeptides or peptides of interest or fragments thereof substantially to the exclusion of other molecules which are random or unrelated, and optionally substantially to the exclusion of other molecules that are structurally related.
  • specifically bind does not necessarily require that an agent binds exclusively to its intended target(s).
  • an agent may be said to specifically bind to protein(s) polypeptide(s), peptide(s) and/or fragment(s) thereof of interest if its affinity for such intended target(s) under the conditions of binding is at least about 2-fold greater, preferably at least about 5-fold greater, more preferably at least about 10-fold greater, yet more preferably at least about 25-fold greater, still more preferably at least about 50-fold greater, and even more preferably at least about 100-fold or more greater, than its affinity for a non-target molecule.
  • the term "antibody” is used in its broadest sense and generally refers to any immunologic binding agent.
  • the term specifically encompasses intact monoclonal antibodies, polyclonal antibodies, multivalent (e.g., 2-, 3- or more-valent) and/or multi-specific antibodies (e.g., bi- or more-specific antibodies) formed from at least two intact antibodies, and antibody fragments insofar they exhibit the desired biological activity (particularly, ability to specifically bind an antigen of interest), as well as multivalent and/or multi-specific composites of such fragments.
  • the term “antibody” is not only inclusive of antibodies generated by methods comprising immunisation, but also includes any polypeptide, e.g.
  • an antibody may be any of IgA, IgD, IgE, IgG and IgM classes, and preferably IgG class antibody.
  • the antibody may be a polyclonal antibody, e.g., an antiserum or immunoglobulins purified there from (e.g., affinity-purified).
  • the antibody may be a monoclonal antibody or a mixture of monoclonal antibodies.
  • Monoclonal antibodies can target a particular antigen or a particular epitope within an antigen with greater selectivity and reproducibility.
  • monoclonal antibodies may be made by the hybridoma method first described by Kohler et al. 1975 (Nature 256: 495), or may be made by recombinant DNA methods (e.g., as in US 4,816,567).
  • Monoclonal antibodies may also be isolated from phage antibody libraries using techniques as described by Clackson et al. 1991 (Nature 352: 624-628) and Marks et al. 1991 (J Mol Biol 222: 581 -597), for example.
  • the antibody binding agents may be antibody fragments.
  • Antibody fragments comprise a portion of an intact antibody, comprising the antigen-binding or variable region thereof.
  • antibody fragments include Fab, Fab', F(ab')2, Fv and scFv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multivalent and/or multispecific antibodies formed from antibody fragment(s), e.g., dibodies, tribodies, and multibodies.
  • the above designations Fab, Fab', F(ab')2, Fv, scFv etc. are intended to have their art-established meaning.
  • the term antibody includes antibodies originating from or comprising one or more portions derived from any animal species, preferably vertebrate species, including, e.g., birds and mammals.
  • the antibodies may be chicken, turkey, goose, duck, guinea fowl, quail or pheasant.
  • the antibodies may be human, murine (e.g., mouse, rat, etc.), donkey, rabbit, goat, sheep, guinea pig, camel (e.g., Camelus bactrianus and Camelus dromaderius), llama (e.g., Lama paccos, Lama glama or Lama vicugna) or horse.
  • an antibody can include one or more amino acid deletions, additions and/or substitutions (e.g., conservative substitutions), insofar such alterations preserve its binding of the respective antigen.
  • An antibody may also include one or more native or artificial modifications of its constituent amino acid residues (e.g., glycosylation, etc.).
  • aptamer refers to single-stranded or double-stranded oligo-DNA, oligo-RNA or oligo-DNA/RNA or any analogue thereof, that can specifically bind to a target molecule such as a the slL7 protein alpha chain or a fragment thereof.
  • aptamers can display fairly high specificity and affinity (e.g., K A in the order 1x10 9 M "1 ) for their targets.
  • photoaptamer refers to an aptamer that contains one or more photoreactive functional groups that can covalently bind to or crosslink with a target molecule.
  • peptidomimetic refers to a non-peptide agent that is a topological analogue of a corresponding peptide.
  • small molecule refers to compounds, preferably organic compounds, with a size comparable to those organic molecules generally used in pharmaceuticals.
  • Preferred small organic molecules range in size up to about 5000 Da, e.g., up to about 4000, preferably up to 3000 Da, more preferably up to 2000 Da, even more preferably up to about 1000 Da, e.g., up to about 900, 800, 700, 600 or up to about 500 Da.
  • any existing, available or conventional separation, detection and quantification methods can be used herein to measure the presence or absence (e.g., readout being present vs. absent; or detectable amount vs. undetectable amount) and/or quantity (e.g., readout being an absolute or relative quantity, such as, for example, absolute or relative concentration) of slL7R and/or fragments.
  • such methods may include immunoassay methods, mass spectrometry analysis methods, or chromatography methods, or combinations thereof.
  • immunoassay generally refers to methods known as such for detecting one or more molecules or analytes of interest in a sample, wherein specificity of an immunoassay for the molecule(s) or analyte(s) of interest is conferred by specific binding between a specific- binding agent, commonly an antibody, and the molecule(s) or analyte(s) of interest.
  • a specific- binding agent commonly an antibody
  • Immunoassay technologies include without limitation direct ELISA (enzyme-linked immunosorbent assay), indirect ELISA, sandwich ELISA, competitive ELISA, multiplex ELISA, radioimmunoassay (RIA), ELISPOT technologies, and other similar techniques known in the art. Principles of these immunoassay methods are known in the art, for example John R. Crowther, "The ELISA Guidebook", 1 st ed., Humana Press 2000, ISBN 0896037282.
  • direct ELISA employs a labelled primary antibody to bind to and thereby quantify target antigen in a sample immobilised on a solid support such as a microwell plate.
  • Indirect ELISA uses a non-labelled primary antibody which binds to the target antigen and a secondary labelled antibody that recognises and allows quantifying the antigen-bound primary antibody.
  • the target antigen is captured from a sample using an immobilised 'capture' antibody which binds to one antigenic site within the antigen, and subsequent to removal of non-bound analytes the so-captured antigen is detected using a 'detection' antibody which binds to another antigenic site within said antigen, where the detection antibody may be directly labelled or indirectly detectable as above.
  • Competitive ELISA uses a labelled 'competitor' that may either be the primary antibody or the target antigen. In an example, non-labelled immobilised primary antibody is incubated with a sample, this reaction is allowed to reach equilibrium, and then labelled target antigen is added.
  • Multiplex ELISA allows simultaneous detection of two or more analytes within a single compartment (e.g., microplate well) usually at a plurality of array addresses (see, for example, Nielsen & Geierstanger 2004. J Immunol Methods 290: 107-20 and Ling et al. 2007. Expert Rev Mol Diagn 7: 87-98 for further guidance).
  • labelling in ELISA technologies is usually by enzyme (such as, e.g., horse-radish peroxidase) conjugation and the end-point is typically colorimetric, chemiluminescent or fluorescent.
  • Radioimmunoassay is a competition-based technique and involves mixing known quantities of radioactively-labelled (e.g., 125 l- or 131 l-labelled) target antigen with antibody to said antigen, then adding non-labelled or 'cold' antigen from a sample and measuring the amount of labelled antigen displaced (see, e.g., "An Introduction to Radioimmunoassay and Related Techniques", by Chard T, ed., Elsevier Science 1995, ISBN 0444821 198 for guidance).
  • radioactively-labelled e.g., 125 l- or 131 l-labelled
  • mass spectrometry methods are suitable for measuring biomarkers.
  • any mass spectrometric (MS) techniques that can obtain precise information on the mass of peptides, and preferably also on fragmentation and/or (partial) amino acid sequence of selected peptides (e.g., in tandem mass spectrometry, MS/MS; or in post source decay, TOF MS), are useful herein.
  • Suitable peptide MS and MS/MS techniques and systems are well- known per se (see, e.g., Methods in Molecular Biology, vol. 146: "Mass Spectrometry of Proteins and Peptides", by Chapman, ed., Humana Press 2000, ISBN 089603609x; Biemann 1990.
  • MS arrangements, instruments and systems suitable for biomarker peptide analysis may include, without limitation, matrix-assisted laser desorption/ionisation time-of- flight (MALDI-TOF) MS; MALDI-TOF post-source-decay (PSD); MALDI-TOF/TOF; surface- enhanced laser desorption/ionization time-of-f light mass spectrometry (SELDI-TOF) MS; electrospray ionization mass spectrometry (ESI-MS); ESI-MS/MS; ESI-MS/(MS) n (n is an integer greater than zero); ESI 3D or linear (2D) ion trap MS; ESI triple quadrupole MS; ESI quadrupole orthogonal TOF (Q-TOF); ESI Fourier transform MS systems; desorption/ionization on silicon (DIOS); secondary ion mass spectrometry (SIMS); atmospheric pressure chemical ionization mass spectrometry (APCI-MS); APCI
  • MS/MS Peptide ion fragmentation in tandem MS
  • CID collision induced dissociation
  • detection and quantification of biomarkers by mass spectrometry may involve multiple reaction monitoring (MRM), such as described among others by Kuhn et al. 2004 (Proteomics 4: 1 175-86).
  • MS peptide analysis methods may be advantageously combined with upstream peptide or protein separation or fractionation methods, such as for example with the chromatographic and other methods described herein below.
  • Chromatography can also be used for measuring biomarkers.
  • the term "chromatography” encompasses methods for separating chemical substances, referred to as such and vastly available in the art.
  • chromatography refers to a process in which a mixture of chemical substances (analytes) carried by a moving stream of liquid or gas ("mobile phase") is separated into components as a result of differential distribution of the analytes, as they flow around or over a stationary liquid or solid phase (“stationary phase”), between said mobile phase and said stationary phase.
  • the stationary phase may be usually a finely divided solid, a sheet of filter material, or a thin film of a liquid on the surface of a solid, or the like.
  • Chromatography is also widely applicable for the separation of chemical compounds of biological origin, such as, e.g., amino acids, proteins, fragments of proteins or peptides, etc.
  • Chromatography as used herein may be preferably columnar (i.e., wherein the stationary phase is deposited or packed in a column), preferably liquid chromatography, and yet more preferably HPLC. While particulars of chromatography are well known in the art, for further guidance see, e.g., Meyer M., 1998, ISBN: 047198373X, and "Practical HPLC Methodology and Applications", Bidlingmeyer, B. A., John Wiley & Sons Inc., 1993.
  • Exemplary types of chromatography include, without limitation, high-performance liquid chromatography (HPLC), normal phase HPLC (NP-HPLC), reversed phase HPLC (RP-HPLC), ion exchange chromatography (I EC), such as cation or anion exchange chromatography, hydrophilic interaction chromatography (HILIC), hydrophobic interaction chromatography (HIC), size exclusion chromatography (SEC) including gel filtration chromatography or gel permeation chromatography, chromatofocusing, affinity chromatography such as immuno- affinity, immobilised metal affinity chromatography, and the like.
  • HPLC high-performance liquid chromatography
  • NP-HPLC normal phase HPLC
  • RP-HPLC reversed phase HPLC
  • I EC ion exchange chromatography
  • I EC ion exchange chromatography
  • HILIC hydrophilic interaction chromatography
  • HIC hydrophobic interaction chromatography
  • SEC size exclusion chromatography
  • gel filtration chromatography or gel permeation chromatography chromat
  • chromatography including single-, two- or more-dimensional chromatography, may be used as a peptide fractionation method in conjunction with a further peptide analysis method, such as for example, with a downstream mass spectrometry analysis as described elsewhere in this specification.
  • peptide or polypeptide separation, identification or quantification methods may be used, optionally in conjunction with any of the above described analysis methods, for measuring biomarkers in the present disclosure.
  • Such methods include, without limitation, chemical extraction partitioning, isoelectric focusing (IEF) including capillary isoelectric focusing (CIEF), capillary isotachophoresis (CITP), capillary electrochromatography (CEC), and the like, one-dimensional polyacrylamide gel electrophoresis (PAGE), two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), capillary gel electrophoresis (CGE), capillary zone electrophoresis (CZE), micellar electrokinetic chromatography (MEKC), free flow electrophoresis (FFE), etc.
  • IEF isoelectric focusing
  • CITP capillary isotachophoresis
  • CEC capillary electrochromatography
  • PAGE polyacrylamide gel electrophoresis
  • 2D-PAGE two-dimensional polyacrylamide gel electrophore
  • the degree of gene expression of said gene or fragment thereof can be measured in e.g. a synovial fluid sample comprising FLS cells that show increased expression of the gene-transcript encoding the soluble form of the IL7 receptor in case of RA.
  • the level of gene expression of the gene is able to distinguish between those patients who will respond well and those patients who will not respond well to a TNF blocking agent.
  • the level of expression of the gene or fragments thereof in a patient whose response status is unknown is compared to the level of expression of the same gene or fragment thereof in patients whose response statue is known. The mathematical similarity between the two expression patterns determines the probability that the unknown patient response will be similar to response of the known patient.
  • the gene expression pattern can be determined in a wide variety of ways including, but not limited to, measuring mRNA levels in a biological sample or measuring protein expression products in a biological sample. These can be performed either ex vivo for example in a blood or serum sample using low-density microarrays, or in vivo after injection of isotopic tracers allowing to identify and quantify the presence of specific markers in affected patients.
  • the TNF blocking agents can be adalimumab (HUMIRA®, Abbott), infliximab (REMICADE®, Schering-Plough), etanercept (ENBREL®, Wyeth), certolizumab pegol (CIMZIA®, UCB) or Golimumab (Schering-Plough).
  • the IL-1 blocking agents can be: blocking antibodies such as canakinumab(llaris) currently tested in juvenile arthritis; Anakinra (Kineret) a recombinant protein (IL-1 receptor antagonist, which competitively binds to the IL-1 receptor and, thereby, blocks IL-1 binding and signal transduction.
  • the IL-17 blocking agents can be: IL-17 blocking antibodies; other biologies such as rituximab (Mabthera)therapy (down-regulating IL-17 production in the synovium), and CTLA4-lg (Orencia) or tocilizumab (Ro-Actemra).
  • rituximab Mobthera
  • CTLA4-lg Orencia
  • tocilizumab Ro-Actemra
  • the level of expression is determined using a method selected from the group consisting of DNA microarray, reverse transcriptase polymerase chain reaction (RT PCR), immunohistochemistry, immunoblotting, and protein microarray.
  • RT PCR reverse transcriptase polymerase chain reaction
  • the level of expression is determined using DNA-microarray, preferably low-density DNA-spotted microarray.
  • the level of expression of said gene or fragment thereof in said biological sample is assessed by detecting the level of expression of at least one transcribed polynucleotide or fragment thereof encoded by said gene or fragment thereof.
  • said at least one transcribed polynucleotide or fragment thereof is a cDNA, or mRNA.
  • the step of detecting further comprises amplifying the transcribed polynucleotide. The step of detecting can be done using the method of quantitative RT PCR.
  • the level of expression of the gene or fragments thereof in said biological sample is assessed by detecting the level of expression of the transcribed polynucleotide or fragments thereof encoded by said gene or fragments thereof.
  • said transcribed polynucleotide or fragments thereof is a cDNA, or mRNA.
  • the level of expression of said gene or fragment thereof is assessed by detecting the presence of at least one transcribed polynucleotide or fragment thereof in a sample, preferably in a serum or synovial fluid sample, with a probe which anneals with the transcribed polynucleotide or fragment thereof under stringent hybridization conditions, known in the art (cf. Sambrook et al., Molecular cloning, a laboratory manual).
  • the present invention therefore also provides arrays comprising probes for detection of polynucleotides (transcriptional state) or for detection of proteins (translational state) in order to detect differentially-expressed genes of the invention.
  • array is intended a solid support or substrate with peptide or nucleic acid probes attached to said support or substrate.
  • Arrays typically comprise a plurality of different nucleic acid or peptide capture probes that are coupled to a surface of a substrate in different, known locations.
  • These arrays also described as “microarrays” or colloquially “chips” have been generally described in the art. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase synthesis methods.
  • oligonucleotide probes that can be used in methods of the present invention.
  • such probes are immobilized on a solid surface as to form an oligonucleotide microarray of the invention.
  • the oligonucleotide probes useful in methods of the present invention are capable of hybridizing under stringent conditions to the at least one, at least two, at least three, at least five, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 100, at least 120, at least 150, at least 180, at least 200, at least 220, at least 240, at least 250, at least 260, at least 264, at least 270, or at least 300 nucleic acids as described herein.
  • the probes in the array are designed so as to detect specifically the gene-transcript or mRNA molecule encoding for the soluble form of the IL7 receptor protein as described herein.
  • the probe may be so designed so as to distinguish between mRNA molecules lacking exon 6 and mRNA molecules comprising exon 6.
  • a planar array surface is preferred, the array may be fabricated on a surface of virtually any shape or even a multiplicity of surfaces.
  • Arrays may be peptides or nucleic acids on beads, gels, polymeric surfaces, and fibers such as fiber optics, glass or any other appropriate substrate. Arrays may be packaged in such a manner as to allow for diagnostics or other manipulation of an all-inclusive device.
  • the step of determination of the level of expression is performed using microarray, preferably DNA-microarray, more preferably low-density DNA-spotted microarray. Suitable probes for said microarray are identified hereunder.
  • a mixture of transcribed polynucleotides obtained from the sample is contacted with a substrate having fixed thereto a polynucleotide complementary to or homologous with at least a portion (e. g. at least 7, 10, 15, 20, 25, 30, 40, 50, 100, 250, 300, or more nucleotide residue) of a RNA transcript encoded by a gene for use in the invention.
  • a polynucleotide complementary to or homologous with a RNA transcript encoded by the gene for use in the invention are differentially detectable on the substrate (e. g. detectable using radioactivity, different chromophores or fluorophores), are fixed to different selected positions, then the levels of expression of a plurality of genes can be assessed simultaneously using a single substrate.
  • an internal control which can be, for example, a known quantity of a nucleic acid derived from a gene for which the expression level is either known or can be accurately determined
  • unknown expression levels of other genes can be compared to the known internal control.
  • an appropriate internal control could be a housekeeping gene (e. g. glucose-6- phosphate dehydrogenase or elongation factor-1 ), a housekeeping gene being defined as a gene for which the expression level in all cell types and under all conditions is substantially the same.
  • This discrete expression level can then be normalized to a value relative to the expression level of the control gene (for example, a housekeeping gene).
  • the term "normalized”, and grammatical derivatives thereof refers to a manipulation of discrete expression level data wherein the expression level of a reference gene is expressed relative to the expression level of a control gene.
  • the expression level of the control gene can be set at 1 , and the expression levels of all reference genes can be expressed in units relative to the expression of the control gene.
  • nucleic acids isolated from a biological sample are hybridized to a microarray, wherein the microarray comprises nucleic acids corresponding to those genes to be tested as well as internal control genes.
  • the genes are immobilized on a solid support, such that each position on the support identifies a particular gene.
  • Solid supports include, but are not limited to nitrocellulose and nylon membranes. Solid supports can also be glass or silicon-based (i.e. gene "chips"). Any solid support can be used in the methods of the presently claimed subject matter, so long as the support provides a substrate for the localization of a known amount of a nucleic acid in a specific position that can be identified subsequent to the hybridization and detection steps.
  • a microarray can be assembled using any suitable method known to one of skill in the art, and any one microarray configuration or method of construction is not considered to be a limitation of the disclosure.
  • the present invention also encompasses a method for predicting the response to a treatment with methotrexate, a TNF blocking agent, IL-1 blocking agents and/or IL-17 blocking agents in a patient, said method comprising:
  • a polynucleotide sample from a biological sample, preferably from a serum or synovial fluid sample, and
  • the present invention also encompasses the use of a probe that hybridizes under stringent conditions to the slL7R-gene-transcript or fragment thereof, preferably the use of probes that hybridizes under stringent conditions to said gene-transcript or fragments thereof, from a biological sample, preferably from a synovial sample; or an antibody that binds to the slL7R protein or fragment thereof, from a biological sample, preferably from a serum sample, for predicting the response to a treatment with a TNF blocking agent in a patient or for diagnosing the severity or disease progression in an RA patient.
  • kits for use in practicing the subject methods.
  • kit refers to any combination of reagents or apparatus that can be used to perform a method of the invention.
  • the kit may comprise a plurality of reagents, each of which is capable of binding specifically with a nucleic acid or polypeptide corresponding to the gene-transcript encoding the soluble IL7 receptor protein for use in the invention.
  • Suitable probe for binding with a nucleic acid include complementary nucleic acids.
  • the nucleic acid reagents may include oligonucleotides (labelled or non-labelled) fixed to a substrate, labeled oligonucleotides not bound with a substrate, pairs of PCR primers, molecular beacon probes, and the like.
  • the kit comprises a nucleic acid probe that binds specifically with a gene nucleic acid or a fragment of the nucleic acid.
  • the kit according to the invention can comprise a protein array enabling the specific and quantitative detection of the soluble form of the IL7 receptor protein, or enabled to detect both the membrane bound and soluble form of the IL7 receptor protein at different spots of the array.
  • further RA-related protein detection means can be present on the array.
  • the kit may comprise a plurality of binding agents, each of which is capable of binding specifically with the soluble IL7R protein, such as antibodies, aptamers, small molecules, peptides etc. as defined above, that are linked to a solid phase using known techniques.
  • the kit may further comprise means for performing a protein detection assay on the array as known in the art.
  • the present invention thud also encompasses a method for predicting the response to a treatment with methotrexate, a TNF blocking agent, IL-1 blocking agents and/or IL-17 blocking agents in a patient, said method comprising:
  • the kit may further comprise means for performing PCR reactions.
  • the kit may further comprise media and solution suitable for taking a sample, preferably a synovial and/or serum sample, and for extracting RNA, respectively protein, from said sample.
  • the kit can further comprise additional components for carrying out the method of the invention, such as RNA extraction solutions, purification column(s) and buffers and the like.
  • the kit of the invention can further include any additional reagents, reporter molecules, buffers, excipients, containers and/or devices as required described herein or known in the art, to practice a method of the invention.
  • kits may be present in separate containers or certain compatible components may be pre-combined into a single container, as desired.
  • the kits may further include instructions for practicing the present invention. These instructions may be present in the kits in a variety of forms, one or more of which may be present in the kit.
  • kits further comprises a computer-readable medium comprising one or more digitally encoded expression profiles, where each profile has one or more values representing the expression of said gene-transcript encoding the soluble IL7 receptor protein or fragment thereof.
  • Said digitally encoded expression profiles are preferably profiles of poor, moderate and good responder to methotrexate or to biologicals including TNF blocking, IL-1 blocking or IL-17 blocking agents.
  • the invention also provides a computer-readable medium comprising one or more digitally encoded expression profiles, where each profile has one or more values representing the expression of the gene-transcript encoding the soluble IL7 receptor protein or fragment thereof that is differentially-expressed in a poor, moderate or good responders to methotrexate or TNF blockade, IL-1 blockade or IL-17 blockade.
  • the digitally-encoded expression profiles are comprised in a database.
  • kits according to the invention may comprise a microarray as defined above and a computer readable medium as described above.
  • the array comprises a substrate having addresses, where each address has a probe that can specifically bind a nucleic acid molecule (by using an oligonucleotide array) or a peptide (by using a peptide array) that is differentially- expressed in at least one poor, moderate or good responder.
  • the results can be converted into a computer-readable medium that has digitally-encoded expression profiles containing values representing the expression level of the nucleic acid molecule or protein detected by the array. Any other convenient means may be present in the kits.
  • Said microarray may be able to specifically detect the membrane-bound form of the IL7 receptor or the gene-transcript encoding therefore at one position and the soluble form of the IL7 receptor protein or the gene-transcript encoding therefore at a different position. This enables the simultaneous detection and quantification of both isoforms in the sample.
  • the microarray may of course encompass further addresses whereon additional relevant markers can be detected and quantified.
  • the invention also provides for the storage and retrieval of a collection of data relating to poor, moderate or good responder to TNF blockade therapy specific gene expression data of the present invention, including expression levels and/or protein amounts or concentrations in a computer data storage apparatus.
  • a collection of data relating to healthy subjects, early RA patients, DMARD-resistant RA patients, or progressed RA patients can be used in the methods and kits according to the invention.
  • the level of expression of said at least one gene or fragment thereof in said patient is assessed by detecting the level of expression of a protein or a fragment thereof encoded by said at least one gene or fragment thereof.
  • the level of expression of said protein or fragment thereof is detected using a reagent which specifically binds with said protein or fragment thereof.
  • Said reagent can be any binding molecule as defined herein e. g. a peptide, an antibody, or a fragment thereof.
  • the level of expression of the mRNA, gene or isoform coding for the slL7R or fragment thereof is detected by measuring or detecting joint uptake of the reagent.
  • said reagent is labeled with a radioactive isotope, which can be detected by radio-imaging.
  • Suitable radioactive isotope can be selected from the group comprising Technetium 99 " 1 , Carbon 11 , Oxygen 15 , Nitrogen 13 , Rubidium 82 , Gallium 67 , Gallium 68 , Yttrium 90 , Molybdenum 99 , Iodine 123 ' 124 ' 131 Fluorine 18 , Phosphorus 32 , Copper 62 , Thallium 201 , Copper 64 , Copper 62 , Indium 111 , and Xenon 133 .
  • Suitable radio-imaging method can be selected from the group consisting of single photon emission computed tomography (SPECT), positron emission tomography (PET) and gamma cameras.
  • SPECT single photon emission computed tomography
  • PET positron emission tomography
  • the method of the invention can also be performed in vivo on a patient after injection of isotopic tracers allowing to identify and quantify the presence of the genes or of the encoded protein thereof in affected patients.
  • the present invention discloses that the soluble IL7R protein is differentially-expressed in poor, moderate or good responders to methotrexate or TNF blockade or, potentially, IL-1 blockade or IL-17 blockade. Accordingly, said protein and the gene encoding it are potential therapeutic targets that are useful in methods of screening test compounds to identify therapeutic compounds for the treatment of rheumatic arthritis.
  • the differentially-expressed slL7R gene or isoform of the invention may be used in cell-based screening assays involving recombinant host cells expressing the differentially-expressed gene product.
  • the recombinant host cells are then screened to identify compounds that can activate the product of the differentially-expressed gene (i.e. agonists) or inactivate the product of the differentially-expressed gene (i.e. antagonists), or increase or decrease its expression.
  • Example 1 Serum soluble interleukin-7 Receptor concentrations predict response to methotrexate in early rheumatoid arthritis and to TNF-blockade in DMARD-resistant rheumatoid arthritis.
  • DMARD-resistant RA patients were 55 ⁇ 12 year old. Disease duration was 10.8 ⁇ 6.7 years. They were treated at baseline with a median 15 mg methotrexate/week schedule (range 7.5 - 25 mg/week). 9% were treated with other DMARD's after having failed methotrexate therapy in the past. 13% were treated with another DMARD together with methotrexate. Patients had taken an average 3 DMARD's including methotrexate (range 1 - 7) before starting infliximab therapy. All of them had erosive changes imaged on conventional x-rays of the hands and/or the feet. They all had active disease at the time of serum sampling (mean DAS28-CRP score: 5.69 ⁇ 1.12).
  • DMARD-resistant RA patients were treated with a standard schedule of infliximab: 3 mg/kg at week 0, week 2, week 6 and then every other month in addition to their DMARD therapy.
  • infliximab 3 mg/kg at week 0, week 2, week 6 and then every other month in addition to their DMARD therapy.
  • DAS-28CRP evaluation were performed between 4 and 6 months after baseline and patients were categorized into non-responders versus responders according to EULAR response criteria (van Gestel et al., Arthritis Rheum 1996 ; 39:34-40).
  • TNF-alpha (R&D Systems, Minneapolis, MN, USA) 10 ng/mL
  • IL-1-beta R&D Systems
  • IL-17 R&D Systems 50 ng/mL.
  • supernatants were collected for slL-7R determination and cells were harvested for total RNA extraction.
  • CD4 T cells were purified from the hyaluronidase- and collagenase-digested synovial biopsies using magnetic beads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to manufacturer's instructions.
  • PBMC from healthy donors were purified by lymphoprep (Nycomed Pharma, Oslo, Norway) density gradient centrifugation. In some experiments, PBMC were cultured for 24 hours in the presence of IL-2 and PHA, and CD4 T cells were purified using magnetic beads (Miltenyi Biotec) as per manufacturer's instructions. CD8 T cells clones (obtained from Pierre van der Bruggen, Ludwig Institute for Cancer Research, Brussels Branch) were stimulated with their cognate antigen presented by irradiated autologous B-EBV cells in the presence of. IL-2 (Chiron, Amsterdam, The Netherlands, 50 U/ml) and IL-7 (R&D Systems, 5 ng/ml).
  • CD8 T cells clones were purified using magnetic beads (Miltenyi Biotec) as per manufacturer's protocol.
  • cDNA from B-EBV cell derived from two healthy donors were obtained from Pierre Coulie (Unite de Genetique Cellulaire, Universite Catholique de Louvain).
  • PCR products were analysed by agarose gel electrophoresis. PCR fragments were gel purified and sequenced using the same primers and the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) before being analysed on a 3130x1 Genetic Analyzer (Applied Biosystems). Quantitative RT- PCR was performed on a MyiQ single-color RT-PCR detection system (Bio-Rad Laboratories, Nazareth Eke, Belgium) using SYBR Green detection mix.
  • cDNA was loaded in triplicate with 1x SYBR Green Mix (Applied Biosystems) and the following 10 rtiM primers: beta-Actin: Forward: ggcatcgtgatggactccg (SEQ ID NO:7) and Reverse: ctggaaggtggacagcga; (SEQ ID NO:8) IL-7R: Forward: ttcttggaggatgcagctaaa (SEQ ID NO:9) and Reverse: aagcccaaccaacaaagagtt (SEQ ID NO:10); slL-7R: Forward: agccaatgactttgtggtgac (SEQ ID NO:1 1 ) and Reverse: tacgataggcttaatcctgag (SEQ ID NO:12).
  • beta-Actin Forward: ggcatcgtgatggactccg (SEQ ID NO:7) and Reverse: ctggaaggtggacagcga
  • the melting curves obtained after each QPCR amplification confirmed the specificity of the SYBR Green assays.
  • Relative expression of the target genes in the studied samples was obtained using the difference in the comparative threshold (AACt) method. Briefly, for each sample, a value for the cycle threshold (Ct) was determined, which was defined as the mean cycle at which the fluorescence curve reached an arbitrary threshold. The ACt for each sample was then calculated according to the formula Ct ta rget gene - Ct ac ti n ; AACt values then were obtained by subtracting the ACt of a reference sample from the ACt of the studied samples. Finally, the levels of expression of the target genes in the studied samples as compared with the reference sample were calculated as 2 "AACt .
  • FLS and PBMC were washed with ice-cold PBS, and lysed in cold lysis buffer (20 mM Hepes pH7.8, 75 mM KCI, 0.1 mM EDTA, 1 mM sodium-orthovanadate, 2 mM MgCI 2 , 1 mM DTT,
  • slL-7R serum titers were determined by sandwich-ELISA in serum samples and culture supernatants using a goat polyclonal hlL-7R antibody (Sigma-Aldrich) as coating antibody and a mouse monoclonal ML-7R antibody as detecting antibody (Sigma-Aldrich). Briefly, Microlon ELISA plates (Greiner Bio One, Wemmel, Belgium) were coated overnight at 4°C with a 100 microliters goat polyclonal hlL-7R antibody solution diluted at 0.5 ⁇ /ml. Plates were blocked with milk and then incubated at 37°C with the control and patient's sera diluted in PBS supplemented with 0.5% BSA. Sera were tested in duplicates.
  • That antibody does not cross-react with human IgG, and is therefore unable to detect IgG rheumatoid factors bound to the coated anti- IL-7R goat antibody.
  • Each incubation step lasted 2 hours. Plates were washed 5 times with PBS Tween (Sigma-Aldrich) 1/1 ,000 between each step. The reactions were revealed with 1- Step Ultra-TMB (Thermo Fisher Scientific) and stopped by the addition of 2M H2S04. The sensitivity of the ELISA is 20 pM/ml.
  • Fibroblast-like synovial cells express two isoforms of the gene encoding the IL-7R alpha-chain.
  • slL-7R expression by FLS is induced by pro-inflammatory cytokines
  • slL-7R inhibits FLS-induced CD4 T-cell proliferation
  • slL-7R is known to display IL-7 binding and blocking properties
  • the present inventors investigated whether it could interfere with synovial CD4 T-cell proliferation.
  • RA FLS are known to express MHC class II molecules and stimulate the proliferation of autologous synovial CD4 T-cells.
  • the results showed that the addition of IL-7 stimulates the proliferation of synovial CD4 T-cells cultured in the presence of autologous FLS.
  • addition of a slL-7R-Fc fusion protein blocks the proliferation of these cells ( Figure 1 D).
  • slL-7R serum levels are higher in RA patients compared to controls
  • slL-7R could also be detected in the much easier accessible serum fluid of healthy individuals and in patients with inflammatory disorders.
  • slL-7R serum levels are higher in DMARD-resistant as compared to early RA patients, an observation suggesting that slL-7R serum levels could be a marker of disease severity and treatment failure.
  • the present inventors established whether baseline slL-7R serum levels are able to predict disease progression and response to therapy in RA. Strikingly, in patients displaying active disease despite DMARD therapy and subsequently treated with TNF blockade, elevated baseline slL-7R serum levels strongly predicted poor-response to anti-TNF therapy ( Figure 4A, 4B and 4C). Conversely, normal baseline slL-7R serum levels were associated with adequate response to therapy, with a sensitivity of 93% and a specificity of 63%.
  • First-line therapy for early RA patients is based on the use of DMARD's such as methotrexate, which induces an adequate response in about 60% of the cases.
  • DMARD's such as methotrexate
  • the present inventors have found that elevated baseline slL-7R serum levels are associated with poor-response to methotrexate therapy in early RA.
  • Example 2 Soluble IL7R levels can help the rheumatologist to make decisions on therapy.
  • Case 1 A 45-year-old patient has severe rheumatoid arthritis and is currently treated with 7.5 mg prednisolone/day, naproxen 1 ,000 mg/day and parenteral methotrexate 20 mg/day, started one year ago. He has 14 tender and 18 swollen joints, including most of the metacarpophalangeal joints. DAS28-CRP score is calculated at 7.3. Anti-citrullin antibodies and rheumatoid factors are positive; x-rays of the hands and feet show erosive and chondrolytic changes at the metacarpo- and metatarsophalangeal joints.
  • the appropriate therapy with biologies for this patient has to be chosen from: 1 ) a TNF-blocker and 2) tocilizumab (anti-IL-6R antibody), since both drugs are available in this indication.
  • a serum slL-7R determination is performed and the results of the test indicate that slL-7R serum titers are in the range of normal. Based on this measurement, the rheumatologist can more easily decide in favour of a treatment with a TNF-blocker, since the probability of the patient to respond to TNF-blocking therapy is calculated as being around 90% in said patient, due to the normal serum slL7R level value.
  • Case 2 A 62-year-old woman suffers from longstanding severe rheumatoid arthritis. She was initially treated with gold salts, next with salazopyrine, hydroxychloroquine and finally 25 mg/week oral methotrexate. She also takes prednisolone 10 mg/day and NSAID's. Her disease is active (DAS28-CRP score 5.4) and conventional x-rays show disease progression in the hands and feet. Her physician decides to initiate therapy with biological agents. Since her slL-7R serum titers are very elevated, the probability that she does not respond to a TNF blocker is evaluated at 75%. For this reason, her rheumatologist prescribes tocilizumab therapy, in stead of TNF-blocking therapy.
  • Case 3 A 33-year-old man suffers from early rheumatoid arthritis, diagnosed based on his clinical presentation (pain and swelling in all metacarpo-phalangeal and proximal interphalangeal joints), high CRP serum levels and positive anti-CCP antibodies. His rheumatologist considers the prescription of first-line DMARD therapy with methotrexate. However, serum slL-7R titers are very high, indicating that the probability of response to methotrexate therapy is low in this patient. For this reason, the rheumatologist urges the patient's insurance company to consider the refunding of a combination therapy of methotrexate together with a biological agent, in order to avoid disease progression and long- term damage.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a identifié slL-7R comme marqueur sérique de l'activation des fibroblastes des lymphocytes CD4 T dans la polyarthrite rhumatoïde (RA). Des taux sériques élevés de slL-7R reflètent l'exposition des cellules synoviales de RA à des combinaisons de cytokines pro-inflammatoires, incluant TNF-alpha, IL-1 bêta, IL-17 et des combinaisons synergétiques de ces cytokines. Des taux sériques élevés de base prédisent une réponse à une thérapie par le méthotrexate chez des patients atteints d'une RA précoce. Des taux sériques élevés de base SlL-7R prédisent fortement une réponse médiocre au blocage du TNF chez les patients résistants à DMARD et, potentiellement une réponse médiocre aux agents bloquants IL-1 et IL-17. L'invention concerne ainsi des procédés et des outils de prédiction de la gravité de la maladie et de la sensibilité d'un sujet au traitement.
PCT/EP2010/050402 2010-01-14 2010-01-14 Procédé d'évaluation de la réponse de patients souffrant de polyarthrite rhumatoïde à une thérapie et procédé de diagnostic de la gravité de la maladie WO2011085811A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/050402 WO2011085811A1 (fr) 2010-01-14 2010-01-14 Procédé d'évaluation de la réponse de patients souffrant de polyarthrite rhumatoïde à une thérapie et procédé de diagnostic de la gravité de la maladie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/050402 WO2011085811A1 (fr) 2010-01-14 2010-01-14 Procédé d'évaluation de la réponse de patients souffrant de polyarthrite rhumatoïde à une thérapie et procédé de diagnostic de la gravité de la maladie

Publications (1)

Publication Number Publication Date
WO2011085811A1 true WO2011085811A1 (fr) 2011-07-21

Family

ID=42077898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/050402 WO2011085811A1 (fr) 2010-01-14 2010-01-14 Procédé d'évaluation de la réponse de patients souffrant de polyarthrite rhumatoïde à une thérapie et procédé de diagnostic de la gravité de la maladie

Country Status (1)

Country Link
WO (1) WO2011085811A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019025624A1 (fr) * 2017-08-03 2019-02-07 Ose Immunotherapeutics Biomarqueurs pour évaluer l'état de réponse à un traitement d'un état ou d'une maladie inflammatoire affectant le tube digestif comme une maladie intestinale inflammatoire chez des patients humains
CN111808882A (zh) * 2020-09-01 2020-10-23 北京百奥赛图基因生物技术有限公司 Il7r基因人源化改造的动物模型的构建方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO2008132176A2 (fr) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Méthode de prévision de la réponse d'un patient à une thérapie bloquant le tnf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO2008132176A2 (fr) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Méthode de prévision de la réponse d'un patient à une thérapie bloquant le tnf

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"An Introduction to Radioimmunoassay and Related Techniques", 1995, ELSEVIER SCIENCE
"Methods in Enzymology", vol. 402, 2005, ACADEMIC PRESS, article "Biological Mass Spectrometry"
"Methods in Molecular Biology", vol. 146, 2000, HUMANA PRESS, article "Mass Spectrometry of Proteins and Peptides"
"Methods in Molecular Biology", vol. 248, 2004, HUMANA PRESS, article "Antibody Engineering: Methods and Protocols"
"Monoclonal Antibodies: A Manual of Techniques", 1987, CRC PRESS
"Monoclonal Antibodies: A Practical Approach", 2000, OXFORD UNIVERSITY PRESS
"The Aptamer Handbook: Functional Oligonucleotides and Their Applications", 2006, WILEY-VCH
ARNETT ET AL., ARTHRITIS RHEUM, vol. 31, 1988, pages 315 - 24
BADOT V ET AL: "Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY 20090423 BIOMED CENTRAL LTD. GBR LNKD- DOI:10.1186/AR2678, vol. 11, no. 2, 23 April 2009 (2009-04-23), XP002577831, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688209/pdf/ar2678.pdf> *
BARDWELL ET AL., RHEUMATOLOGY (OXFORD), vol. 41, no. 1, January 2002 (2002-01-01), pages 38 - 45
BIEMANN, METHODS ENZYMOL, vol. 193, 1990, pages 455 - 79
CABRAL ET AL., ARTHRITIS RHEUM, vol. 53, 2005, pages 61 - 66
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
DE BARI ET AL., ARTHRITIS RHEUM, vol. 44, 2001, pages 1928 - 1942
ELLINGTON; SZOSTAK, NATURE, vol. 346, 1990, pages 818 - 822
FAUCHER ET AL., PLOS ONE, vol. 4, 2009, pages E6690
GOODWIN ET AL., CELL, vol. 60, 1990, pages 941 - 51
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOUR LABORATORY
HARLOW; LANE: "Using Antibodies: A Laboratory Manual", 1999, COLD SPRING HARBOUR LABORATORY
HARTGRING SARITA A Y ET AL: "Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis.", ARTHRITIS AND RHEUMATISM SEP 2009 LNKD- PUBMED:19714586, vol. 60, no. 9, September 2009 (2009-09-01), pages 2595 - 2605, XP002577833, ISSN: 0004-3591 *
HORWELL, TRENDS BIOTECHNOL, vol. 13, 1995, pages 132 - 134
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KUHN ET AL., PROTEOMICS, vol. 4, 2004, pages 1175 - 86
LINDBERG JOHAN ET AL: "Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB LNKD- DOI:10.1186/AR2090, vol. 8, no. 6, 29 November 2006 (2006-11-29), pages R179, XP021026935, ISSN: 1478-6354, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1794525/pdf/ar2090.pdf> *
LING ET AL., EXPERT REV MOL DIAGN, vol. 7, 2007, pages 87 - 98
MALEMUD CHARLES J: "The discovery of novel experimental therapies for inflammatory arthritis.", MEDIATORS OF INFLAMMATION 2009 LNKD- PUBMED:20339519, vol. 2009, 2009, pages 698769, XP002577834, ISSN: 1466-1861 *
MARKS ET AL., J MOL BIOL, vol. 222, 1991, pages 581 - 597
MEYER M.: "Practical HPLC Methodology and Applications", 1993, JOHN WILEY & SONS INC.
NIELSEN; GEIERSTANGER, J IMMUNOL METHODS, vol. 290, 2004, pages 107 - 20
O'DOHERTY C ET AL: "IL7RA polymorphisms and chronic inflammatory arthropathies.", TISSUE ANTIGENS NOV 2009 LNKD- PUBMED:19744146, vol. 74, no. 5, November 2009 (2009-11-01), pages 429 - 431, XP002577832, ISSN: 1399-0039 *
PLEIMAN ET AL., MOL CELL BIOL, vol. 11, 1991, pages 3052 - 9
PREVOO ET AL., ARTHRITIS RHEUM, vol. 38, 1995, pages 44 - 48
ROSE ET AL., J IMMUNOL, vol. 182, 2009, pages 7389 - 97
TING ET AL., J RHEUMATOL, vol. 32, 2005, pages 1679 - 1687
TUERK; GOLD, SCIENCE, vol. 249, 1990, pages 505 - 510
VAN DER HEIJDE ET AL., J RHEUMATOL, vol. 20, 1993, pages 579 - 581
VAN GESTEL ET AL., ARTHRITIS RHEUM, vol. 39, 1996, pages 34 - 40

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019025624A1 (fr) * 2017-08-03 2019-02-07 Ose Immunotherapeutics Biomarqueurs pour évaluer l'état de réponse à un traitement d'un état ou d'une maladie inflammatoire affectant le tube digestif comme une maladie intestinale inflammatoire chez des patients humains
US12077820B2 (en) 2017-08-03 2024-09-03 Ose Immunotherapeutics Biomarkers for assessing the response status for treatment of Inflammatory condition or disease affecting the digestive tract such as inflammatory bowel disease in human patients
CN111808882A (zh) * 2020-09-01 2020-10-23 北京百奥赛图基因生物技术有限公司 Il7r基因人源化改造的动物模型的构建方法及其应用

Similar Documents

Publication Publication Date Title
JP6404208B2 (ja) 特発性肺線維症の予後予測、診断および処置の方法
JP5998318B2 (ja) 新規血管炎の検査方法および検査用試薬
US20190367984A1 (en) Methods for predicting response to anti-tnf therapy
AU2016323579A1 (en) Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers
US20140205613A1 (en) Anti-tnf and anti-il 17 combination therapy biomarkers for inflammatory disease
WO2017196432A1 (fr) Compositions et méthodes de diagnostic et de traitement d&#39;une maladie neurodégénérative
KR20180096633A (ko) Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20
EP3440461A1 (fr) Prédiction de la réponse anti-tnf dans des biopsies de côlon avec les proportions de cellules immunitaires infiltrantes
WO2020104705A9 (fr) Prédiction d&#39;une réponse à un traitement dans une maladie intestinale inflammatoire
Wang et al. Molecular profiling and clonal tracking of secreted rheumatoid factors in primary Sjögren's syndrome
US10458996B1 (en) Methods for determining clinical response to TNF-alpha and/or JAK inhibitors in subjects with inflammatory diseases
JP6347477B2 (ja) 関節リウマチ患者に対する抗ｉｌ−６受容体抗体治療の有効性予測方法
EP4182691A2 (fr) Biomarqueurs et classificateur du psoriasis et méthodes de traitement
JP2013213774A (ja) 結核検査用バイオマーカー
US20120077689A1 (en) Compartment-Specific Non-HLA Targets for Diagnosis and Prediction of Graft Outcome
WO2014155278A2 (fr) Méthodes de traitement de maladies auto-immunes à l&#39;aide d&#39;antagonistes de l&#39;il -17
WO2011085811A1 (fr) Procédé d&#39;évaluation de la réponse de patients souffrant de polyarthrite rhumatoïde à une thérapie et procédé de diagnostic de la gravité de la maladie
EP2954325B1 (fr) Diagnostic de polyarthrite rhumatoïde
US20110177966A1 (en) method for predicting the response to a treatment with anakinra
JP2013021932A (ja) 関節リウマチに対する抗ｉｌ−６受容体抗体療法の有効性の予測方法
US20220364174A1 (en) Methods for determining responsiveness to anti-tumor necrosis factor therapy in the treatment of psoriasis
US20150369823A1 (en) Method to identify patients that will likely respond to anti-tnf therapy
WO2015081067A2 (fr) Marqueurs biologiques de mélanome métastasique
US11779643B2 (en) Methods and compositions for the treatment of an inflammatory bowel disease
KR101883788B1 (ko) 메토트렉세이트의 치료 반응성 진단용 조성물 및 이를 이용한 진단 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10702264

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10702264

Country of ref document: EP

Kind code of ref document: A1